AAPG

Ascentage Pharma Group International (AAPG) ESG Analysis Analysis (2026)

Invetso Score: 4.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

High gross margin and low capex intensity suggest limited direct environmental footprint relative to sales.

Negative operating cash flow and weak profitability limit the ability to fund sustainability initiatives.

Social

Large working capital and cash balances support employee and supplier continuity despite weak earnings.

Very high days of sales outstanding and negative margins point to operational strain that can pressure stakeholders.

Governance

Strong liquidity and modest net debt reduce near-term balance-sheet governance risk.

However, negative returns on capital and poor cash conversion indicate weak capital allocation discipline.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ascentage Pharma Group International. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →